

CURRICULUM VITAE

Philippe CAMUS

Born 24 April 1950 in Strasbourg, Bas-Rhin, Elsass, France

French citizen

MD Dijon, June 1978

Resident, University Hospital at Poitiers France 1973-1974

Resident University Hospital at Dijon, 1974-1979

Board Pulmonary Disease, 1976, Paris, France

Board Cardiovascular Medicine, 1978; Paris France

Assistant Professor in Pulmonary Medicine Dijon, France 1979-1984

Senior Research Associate. Department of Pharmacology and Toxicology. University of Mississippi Medical Center. Jackson MS 1984-1985

Full Professor Pulmonology and Consulting Physician. Université de Bourgogne and University Medical Center at Dijon 1985 onward

Chairman and Head Department Pulmonary Medicine and Critical Care 1998 - 2014

Professional data : Ordre des Médecins de Côte d'Or N° 21/1995 - 10-003-788-204

Fields of interest:

- Drug disposition in lung
- Drug-induced and iatrogenic lung disease
- The Pneumotox website (www.pneumotox.com) since 1997 (approximately 800-1000 daily users/hits)
- The lung in inflammatory bowel disease, Ulcerative Colitis and Crohn's Disease
- Mechanisms of pulmonary and pleural fibrosis

Member of the American Thoracic Society since 1978

Member of the European Respiratory Society. Member since 1988

Editorial Board member European Respiratory Journal, *ca.* 1996-1998, Respiration 1997-2017

Reviewer for European Respiratory Journal, Thorax, Respiratory Medicine, American Journal of Respiratory and Critical Care Medicine

Publications

Cormier YF, Camus P, Desmeules MJ. Non-organic acute upper airway obstruction: description and a diagnostic approach. The American review of respiratory disease 1980; 121: 147-50

2-Camus P, Degat OR, Justrabo E, Jeannin L. D-Penicillamine-induced severe pneumonitis. Chest 1982; 81: 376-8

3-Cox C, Camus P, Duvivier J. An enzymatic cycling procedure for NAD⁺ using an irreversible reaction with NAD⁺-peroxidase. Analytical biochemistry 1982; 119: 185-93

4-Camus P, Jeannin L. Re: Speculation on the mechanism for amiodarone-induced pneumonitis. Radiology 1984; 150: 279-80

5-Camus P, Jeannin L. The diseased lung and drugs. Archives of toxicology Supplement = Archiv fur Toxikologie Supplement 1984; 7: 66-87

6-Camus P, Mehendale HM. Pulmonary sequestration of amiodarone and desethylamiodarone. The Journal of pharmacology and experimental therapeutics 1986; 237: 867-73

7-Camus P, Lombard JN, Perrichon M, Piard F, Guerin JC, Thivolet FB, Jeannin L. Bronchiolitis obliterans organising pneumonia in patients taking acebutolol or amiodarone. Thorax 1989; 44: 711-5

8-Coudert B, Bailly F, Lombard JN, Andre F, Camus P. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 1992; 102: 1005-12

9-Dautzenberg B, Scheimberg A, Brambilla C, Camus P, Godard P, Guerin JC, Lemarie E, Rezvani Y, Rosebaum M, Tuchais E, et al. Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections. Diagnostic microbiology and infectious disease 1992; 15: 85S-89S

10-Dumas M, Dubuet A, D'Athis P, Camus P, Escousse A. Comparative pharmacokinetics of tetrahydropyranyl-doxorubicin and doxorubicin in rat isolated lung. The Journal of pharmacy and pharmacology 1992; 44: 58-60

11-Pfitzenmeyer P, Foucher P, Piard F, Coudert B, Braud ML, Gabez P, Lacroix S, Mabile JP, Camus P. Nilutamide pneumonitis: a report on eight patients. Thorax 1992; 47: 622-7

12-Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine 1993; 72: 151-83

13-Lombard JN, Bonnotte B, Maynadie M, Foucher P, Reybet Degat O, Jeannin L, Camus P. Celiprolol pneumonitis. The European respiratory journal 1993; 6: 588-91

14-Pfitzenmeyer P, Meier M, Zuck P, Peiffer G, Masson P, Turcu A, Piard F, Camus P. Piroxicam induced pulmonary infiltrates and eosinophilia. The Journal of rheumatology 1994; 21: 1573-7

- 15-**Sitbon O, Bidel N, Dussopt C, Azarian R, Braud ML, Lebargy F, Fourme T, de Blay F, Piard F, Camus P.** Minocycline pneumonitis and eosinophilia. A report on eight patients. Archives of internal medicine 1994; 154: 1633-40
- 16-**Foucher P, Merati M, Baudouin N, Reybet-Degat O, Camus P, Jeannin L.** Fatal ball-valve airway obstruction by an extensive blood clot during mechanical ventilation. The European respiratory journal 1996; 9: 2181-2
- 17-**Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P, Piard F, Camus P.** Pleuropulmonary changes induced by ergoline drugs. The European respiratory journal 1996; 9: 1013-9
- 18-**Camus P.** Respiratory disease induced by drugs. The European respiratory journal 1997; 10: 260-4
- 19-**De Vuyst P, Pfitzenmeyer P, Camus P.** Asbestos, ergot drugs and the pleura. The European respiratory journal 1997; 10: 2695-8
- 20-**Foucher P, Biour M, Blayac JP, Godard P, Sgro C, Kuhn M, Vergnon JM, Vervloet D, Pfitzenmeyer P, Ollagnier M, Mayaud C, Camus P.** Drugs that may injure the respiratory system. The European respiratory journal 1997; 10: 265-79
- 21-**Camus P, Hillerdal G, De Vuyst P.** Asbestos, ergot drugs and the pleura. The European respiratory journal 1998; 11: 1427
- 22-**Camus P, Nemery B.** A novel cause for bronchiolitis obliterans organizing pneumonia: exposure to paint aerosols in textile workshops. The European respiratory journal 1998; 11: 259-62
- 23-**Foucher P, Heeringa P, Petersen AH, Huitema MG, Brouwer E, Tervaert JW, Prop J, Camus P, Weening JJ, Kallenberg CG.** Antimyeloperoxidase-associated lung disease. An experimental model. American journal of respiratory and critical care medicine 1999; 160: 987-94
- 24-**Maillard N, Foucher P, Caillot D, Durand C, Sgro C, Camus P.** Transient pulmonary infiltrates during treatment with anti-thymocyte globulin. Respiration; international review of thoracic diseases 1999; 66: 279-82
- 25-**Camus P.** Drug history and remote exposure to drugs. A cause of lung disease? The European respiratory journal 2000; 16: 381-4
- 26-**Camus P, Colby TV.** The lung in inflammatory bowel disease. The European respiratory journal 2000; 15: 5-10
- 27-**De Vuyst P, Camus P.** The past and present of pneumoconioses. Current opinion in pulmonary medicine 2000; 6: 151-6
- 28-**Camus PH, Foucher P, Bonniaud PH, Ask K.** Drug-induced infiltrative lung disease. The European respiratory journal Supplement 2001; 32: 93s-100s
- 29-**Nemery B, Bast A, Behr J, Borm PJ, Bourke SJ, Camus PH, De Vuyst P, Jansen HM, Kinnula VL, Lison D, Pelkonen O, Saltini C.** Interstitial lung disease induced by exogenous agents: factors governing susceptibility. The European respiratory journal Supplement 2001; 32: 30s-42s
- 30-**Ask K, Dijols S, Giroud C, Casse L, Frapart YM, Sari MA, Kim KS, Stuehr DJ, Mansuy D, Camus P, Boucher JL.** Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug. Chemical research in toxicology 2003; 16: 1547-54
- 31-**Ask K, Decolonne N, Asare N, Holme JA, Artur Y, Pelczar H, Camus P.** Distribution of nitroreductive activity toward nilutamide in rat. Toxicology and applied pharmacology 2004; 201: 1-9
- 32-**Camus P.** Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. British journal of cancer 2004; 91 Suppl 2: S1-2

- 33-**Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P**. Drug-induced and iatrogenic infiltrative lung disease. *Clinics in chest medicine* 2004; 25: 479-519, vi
- 34-**Camus P, Fanton A, Bonniaud P, Camus C, Foucher P**. Interstitial lung disease induced by drugs and radiation. *Respiration; international review of thoracic diseases* 2004; 71: 301-26
- 35-**Camus P, Kudoh S, Ebina M**. Interstitial lung disease associated with drug therapy. *British journal of cancer* 2004; 91 Suppl 2: S18-23
- 36-**Camus P, Martin WJ, 2nd, Rosenow EC, 3rd**. Amiodarone pulmonary toxicity. *Clinics in chest medicine* 2004; 25: 65-75
- 37-**Camus P, Rosenow EC, 3rd**. Iatrogenic lung disease. *Clinics in chest medicine* 2004; 25: XIII-XIX
- 38-**Camus P, Costabel U**. Drug-induced respiratory disease in patients with hematological diseases. *Seminars in respiratory and critical care medicine* 2005; 26: 458-81
- 39-**Ask K, Decolonne N, Ginies C, Lag M, Boucher JL, Holme JA, Pelczar H, Camus P**. Metabolism of nilutamide in rat lung. *Biochemical pharmacology* 2006; 71: 377-85
- 40-**Bonnaud P, Favrolt N, Collet E, Dumas JP, Guilloux L, Pauli G, Camus P**. Salbutamol, terbutaline and pirbuterol allergy in an asthmatic patient. *Allergy* 2007; 62: 1219-20
- 41-**Decolonne N, Kolb M, Margetts PJ, Menetrier F, Artur Y, Garrido C, Gauldie J, Camus P, Bonniaud P**. TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. *Journal of immunology (Baltimore, Md : 1950)* 2007; 179: 6043-51
- 42-**Guenther A, Eickelberg O, Preissner KT, Chambers R, Laurent G, Wells A, Crestani B, Vancheri C, Bonniaud P, Camus P, Schmitz G, Klepetko W, Schultze J, Vossmeier D, Stumpf P**. International registry for idiopathic pulmonary fibrosis. *Thorax* 2008; 63: 841; author reply 841
- 43-**Rabec C, Georges M, Kabeya NK, Baudouin N, Massin F, Reybet-Degat O, Camus P**. Evaluating noninvasive ventilation using a monitoring system coupled to a ventilator: a bench-to-bedside study. *The European respiratory journal* 2009; 34: 902-13
- 44-**Decolonne N, Wettstein G, Kolb M, Margetts P, Garrido C, Camus P, Bonniaud P**. Bleomycin induces pleural and subpleural fibrosis in the presence of carbon particles. *The European respiratory journal* 2010; 35: 176-85
- 45-**White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ**. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. *American journal of respiratory and critical care medicine* 2010; 182: 396-403
- 46-**Bonnaud P, Georges M, Blanc-Caille M, Collet E, Camus P**. Salbutamol inhaler misuse resulting in skin burn. *The Journal of allergy and clinical immunology* 2011; 127: 295
- 47-**Camus P, Colby TV**. Bronchiectasis in inflammatory bowel disease. *European Respiratory Monographs* 2011; 52: 163-177
- 48-**Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P**. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology* 2012; 23: 1943-53
- 49-**Lhoumeau A, Pernet J, Georges M, Devilliers Y, Charles Dalphin J, Camus P, Bonniaud P**. Hypersensitivity pneumonitis due to isocyanate exposure in an airbag

"welder". *European respiratory review* : an official journal of the European Respiratory Society 2012; 21: 168-9

50-**Cottin V, Camus P**. Practical issues and challenges in idiopathic pulmonary fibrosis. *Respiration; international review of thoracic diseases* 2013; 86: 1-4

51-**Saad N, Camus P, Suissa S, Ernst P**. Statins and the risk of interstitial lung disease: a cohort study. *Thorax* 2013; 68: 361-4

52-**Stoclin A, Delbos F, Dauriat G, Brugiere O, Boeri N, Metivier AC, Thabut G, Camus P, Mal H**. Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient. *Vox sanguinis* 2013; 104: 175-8

53-**Bellaye PS, Wettstein G, Burgy O, Besnard V, Joannes A, Colas J, Cause S, Marchal-Somme J, Fabre A, Crestani B, Kolb M, Gauldie J, Camus P, Garrido C, Bonniaud P**. The small heat-shock protein alphaB-crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis. *The Journal of pathology* 2014; 232: 458-72

54-**Camus P, von der Thusen J, Hansell DM, Colby TV**. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? *The European respiratory journal* 2014; 44: 289-96

55-**Abdulmalak C, Cottenet J, Beltramo G, Georges M, Camus P, Bonniaud P, Quantin C**. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. *The European respiratory journal* 2015; 46: 503-11

56-**Bellaye PS, Burgy O, Colas J, Fabre A, Marchal-Somme J, Crestani B, Kolb M, Camus P, Garrido C, Bonniaud P**. Antifibrotic role of alphaB-crystallin inhibition in pleural and subpleural fibrosis. *American journal of respiratory cell and molecular biology* 2015; 52: 244-52

57-**Cottin V, Bergot E, Bourdin A, Cadranel J, Camus P, Crestani B, Dalphin JC, Delaval P, Dromer C, Israel-Biet D, Kessler R, Marchand-Adam S, Marquette CH, Prevot G, Reynaud-Gaubert M, Valeyre D, Wallaert B, Bouquillon B, Cordier JF**. Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. *ERJ open research* 2015; 1:

58-**Giraud V, Longvert C, Houlle-Crepin S, Danel C, Labrune S, Camus P, Saiag P, Chinet T**. Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. *BMC cancer* 2015; 15: 732

59-**Bonniaud P, Georges M, Abdulmalak C, Beltramo G, Cottenet J, Camus P, Quantin C**. Haemoptysis: a frequent diagnostic challenge. *The European respiratory journal* 2016; 47: 350-1

60-**Burgy O, Wettstein G, Bellaye PS, Decologne N, Racoeur C, Goirand F, Beltramo G, Hernandez JF, Kenani A, Camus P, Bettaieb A, Garrido C, Bonniaud P**. Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity. *Science translational medicine* 2016; 8: 326ra20

61-**Georges M, Nguyen-Baranoff D, Griffon L, Foignot C, Bonniaud P, Camus P, Pepin JL, Rabec C**. Usefulness of transcutaneous PCO₂ to assess nocturnal hypoventilation in restrictive lung disorders. *Respirology (Carlton, Vic)* 2016; 21: 1300-6

62-**Quilot FM, Georges M, Favrolt N, Beltramo G, Foignot C, Grandvullemin A, Montani D, Bonniaud P, Camus P**. Pulmonary hypertension associated with ponatinib therapy. *The European respiratory journal* 2016; 47: 676-9

63-**Cottin V, Crestani B, Cadranel J, Cordier JF, Marchand-Adam S, Prevot G, Wallaert B, Bergot E, Camus P, Dalphin JC, Dromer C, Gomez E, Israel-Biet D, Jouneau S, Kessler R, Marquette CH, Reynaud-Gaubert M, Aguilaniu B, Bonnet D, Carre P, Danel C, Faivre JB, Ferretti G, Just N, Lebargy F, Philippe B, Terrioux P, Thivolet-Bejui F, Trumbic B, Valeyre D**. French practical guidelines for the diagnosis

and management of idiopathic pulmonary fibrosis: 2017 update. Summary. Revue des maladies respiratoires 2017:

64-Jullian-Desayes I, Revol B, Chareyre E, Camus P, Villier C, Borel JC, Pepin JL, Joyeux-Faure M. Impact of concomitant medications on obstructive sleep apnoea. British journal of clinical pharmacology 2017; 83: 688-70

Website

Pneumotox. Producer: Ph Camus, 2017. (Accessed at <http://www.pneumotox.com>. Last update: October 15, 2017)

October 24, 2017

Philippe Camus